MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies

Overexpression of anti-apoptotic BCL-2 family members is a hallmark of many lymphoid malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) that can be targeted with small molecule inhibitors. ABT-199 is a rationally designed BCL-2 homology (BH)-3 mimetic that spec...

Descripción completa

Detalles Bibliográficos
Autores principales: Choudhary, G S, Al-harbi, S, Mazumder, S, Hill, B T, Smith, M R, Bodo, J, Hsi, E D, Almasan, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669737/
https://www.ncbi.nlm.nih.gov/pubmed/25590803
http://dx.doi.org/10.1038/cddis.2014.525

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669737/
https://www.ncbi.nlm.nih.gov/pubmed/25590803
http://dx.doi.org/10.1038/cddis.2014.525

Ejemplares similares